Peripartum substitution of inhaled for intravenous prostacyclin in a patient with primary pulmonary hypertension

Anesthesiology

Volumn 100, Issue 6, 2004, Pages 1603-1605

  Hill, Laureen L ^a   De Wet, Charl J ^a   Jacobsohn, Eric ^a   Leighton, Barbara L ^a   Tymkew, Heidi ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYTOCIN; PROSTACYCLIN;

ADULT; ARTICLE; CASE REPORT; CHILDBIRTH; FEMALE; FORCEPS DELIVERY; HUMAN; LABOR INDUCTION; NEBULIZER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 2542496741     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200406000-00037     Document Type: Article

References (12)

1. De Wet C, Jacobsohn E, Zanaboni P, Tymkew H, Smith J, Hill L, Avidan M: Inhaled prostacyclin (PGI2) is safe and more affordable than inhaled nitric oxide as a selective pulmonary vasodilator in cardiothoracic surgical patients. Anesth Analg 2003; 96:SCA 120
2. Hache M, Denault AY, Belisle S, Couture P, Babin D, Tetrault F, Guimond JG: Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. Can J Anaesth 2001: 48:924-9
3. Mikhail G, Gibbs J, Richardson M, Wright G, Khaghani A, Banner N, Yacoub M: An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997; 18:1499-504
4. Weiss BM, Zemp L, Seifert B, Hess OM: Outcome of pulmonary vascular disease in pregnancy: A systematic overview from 1978 through 1996. J Am Coll Cardiol 1998; 31:1650-7
5. Tsou E, Waldhorn RE, Kerwin DM, Katz S, Patterson JA: Pulmonary venoocclusive disease in pregnancy. Obstet Gynecol 1984; 64:281-4
6. Smedstad KG, Cramb R, Morison DH: Pulmonary hypertension and pregnancy: A series of eight cases. Can J Anaesth 1994; 41:502-12
7. Zwissler B, Kemming G, Habler O, Kleen M, Merkel M, Haller M, Briegel J, Welte M, Peter K: Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:1671-7
8. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U, Bergh CH, Ricksten SE: Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 1998; 114:780-6
9. Haraldsson A, Kieler-Jensen N, Wadenvik H, Ricksten SE: Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypass. Intensive Care Med 2000; 26:188-94
10. van Heerden PV, Gibbs NM, Michalopoulos N: Effect of low concentrations of prostacyclin on platelet function in vitro. Anaesth Intensive Care 1997; 25:343-6
11. van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL: Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000; 117:819-27
12. Rao GH, Reddy KR, Hagert K, White JG: Influence of pH on the prostacyclin (PGI2) mediated inhibition of platelet function. Prostaglandins Med 1980; 4:263-73